Latest From Kaneka Corp.
Online, pamphlet claims trip Baker's Best; MusclePharm maintains turnaround progress; Kameka enters probiotic market through AB-Biotics; and POM Wonderful ad swims on humor.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced May-June 2014.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced April through May 2014.
Novartis OTC plant not “out of the woods”; ERSP questions Calmestra claims; GSK seeks to switch Pirinase Hayfever Relief to GSL in U.K.; Kaneka raises CoQ10 prices; FTC to disburse consumer refund for Iovate supplements; more In brief.
- Medical Devices
- Therapeutic Areas
- Pacific Rim
- Parent & Subsidiaries
- Kaneka Corp.
- Senior Management
Mamoru Kadokura, Pres.
Tsuyoshi Sakata, Exec. Dir., Pharmaceutical R&D
Haru Hatano, Exec. Dir., R&D
- Contact Info
Phone: (81) 6 6226 5050
3-2-4 Nakanoshima, Kita-ku
Osaka, 530 8288
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.